Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 245

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 245
---
jections were fairly recent and still reflected the view of Longevity’s management. Accordingly, the FutureTech Board did
not consider obtaining updated projections prior to signing the Merger Agreement. As of the date of this filing, the Projections still
reflect Longevity’s management’s views on future performance.

Material Assumptions for
the Projections by Product Candidate

The material
assumptions and beliefs for each product candidate which Longevity’s management used in preparing the Projections are presented
below:

LBI-001 Retinal Vein Occlusion

| ● | Target markets and geographical sales territories would include the United States, Europe (primarily Western                            
 Europe) and China. Market sizes in the forecasted years of market launch include treatable cases of approximately 119,000, 273,000 and  
 615,000 in the United States, Europe and China, respectively. The treatable cases are management’s best estimation after performing     
 a comprehensive review of published medical literature to determine starting incidence rates, annual growth rates, spontaneous recovery 
 rates and percent stratification between central and branch retinal vein occlusion cases.                                               |

| ● | Market growth in relation to the number of treatable cases of 2% annually for all target markets with                                   
 peak market penetration of 33% achieved six years after product launch for each of the United States, Europe and China. The 2% growth   
 rate was determined based on published medical literature and the estimated market penetration rate is based on management’s collective 
 experience in the field after reviewing the current competitive                                                                         
 landscape relative to alternative retinal vein occlusion therapies currently on the market.                                             |

| ● | The projected realized pricing was determined by reviewing the prices for existing products for the treatment                       
 for retinal vein occlusion and establishing a comparable and competitive price point relative to existing treatments in the market. |

| ● | Conduct a Phase 2 study of 50 subjects to begin upon consummation of the Business Combination and conclude                                 
 in the second half of 2026 at a cost of approximately $21,000 per subject. Additional costs include project management, training, clinical 
 monitoring, data management, biostatistics, safety, clinical device costs and regulatory submissions.                                      |

| ● | Conduct a pivotal Phase 3 study of 450 subjects to begin in mid-2027 and be completed in mid-2028 at a                                  
 cost of approximately $11,000 per subject. Additional costs include project management, training, clinical monitoring, data management